As part of the trial, up to 30 healthy males with androgenic alopecia will be split into five cohorts. Credit: Daniel VG/

OliX Pharmaceuticals has administered the first patient with its RNAi therapeutic, OLX72021, in a Phase I trial to treat androgenic alopecia, also called male-pattern baldness.

The administration was carried out at a designated clinical study facility in Australia.

After securing approval for the trial from Australia’s Bellberry Human Research Ethics Committee (Bellberry HREC) this March, OliX started patient enrolment.

The trial’s primary objective is to examine the safety, tolerability, and pharmacokinetics of OLX72021 given through a single intradermal injection.

The trial splits up to 30 healthy males with androgenic alopecia into five cohorts, with eight weeks follow-up monitoring following intradermal injection of OLX72021 in several dosages, or a placebo, in six alopecia areas near the patients’ crown.

OLX72021 has the capability to suppress the hormone activity that leads to androgenic alopecia by minimising the androgen receptor (AR) expression.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In pre-clinical studies, OLX72021 showed long-term efficacy. The therapy is anticipated to reduce the inconvenience of current hair loss treatments that need frequent injection or administration.

As OLX72021 is topically injected into the scalp and degraded quickly when exposed to the blood after maintaining high concentration only in subcutaneous hair loss areas, it may not cause the same side effects and limitations, including sexual dysfunction or depression, as current hair loss treatments.

OliX received a patent for the therapy in 2021 in the US.

Following the confirmation of safety of OLX72021 in human bodies in the Phase I trial in Australia, the company plans to introduce new hair loss cosmeceuticals in the future.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.